The global transdermal skin patches market is estimated to be valued at USD 8.79 Bn in 2024 and is expected to exhibit a CAGR of 5.5% during the forecast period (2024-2031). The global transdermal skin patches market has been gaining traction over the past few years owing to the growing prevalence of various chronic diseases globally. Transdermal skin patches provide a convenient mode of delivery of drugs and offer several advantages over conventional drug delivery methods. These patches administer medication through the skin and into the bloodstream at a predetermined rate for an intended duration. They minimize gastric irritation caused by oral administration of drugs and provide controlled release of drug for an extended period of time. Moreover, transdermal skin patches offer non-invasive and painless delivery of drugs, which enhances patient compliance in therapy. Rising geriatric population, increasing demand for self-administration of drugs, and growing need for convenient drug delivery systems are some of the key factors anticipated to fuel the demand for transdermal skin patches in the coming years.

Market Dynamics:

Growing prevalence of chronic diseases, such as cardiovascular disorders, diabetes, chronic pain, cancer, and neurological disorders, is a key factor boosting the adoption of transdermal skin patches globally. Moreover, the rising geriatric population who are more prone to develop chronic conditions is also augmenting the market growth. The growing preference of patients and care-givers for non-invasive and needle-free drug delivery systems owing to convenience and ease-of-use is further propelling the demand for transdermal skin patches. On the other hand, high development costs associated with transdermal patch-based drug delivery systems and regulatory challenges pertaining to clinical trials are some of the factors expected to restrain the market growth to a certain extent over the forecast period. However, ongoing advancements in formulation technologies are aimed at enhancing delivery rates of a wider range of drugs. This is expected to offer lucrative growth opportunities for players in this market.

Key Features of the Study:

• This report provides an in-depth analysis of the global transdermal skin patches market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global transdermal skin patches market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Novartis AG, Purdue Pharma L.P., Viatris, Inc., Teikoku Pharma USA, Inc., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., LUYE PHARMA AG, Samyang Holdings Corporation, Vektor Pharma, Hisamitsu Pharmaceutical Co.,Inc., UCB S.A., Hikma Pharmaceuticals PLC , Corium, Inc., Nitto Denko Corporation, Gedeon Richter Plc., Agile Therapeutics, Amneal Pharmaceuticals LLC., Cipla, and AdhexPharma
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global transdermal skin patches market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transdermal skin patches market.

Detailed Segmentation-

• By Type:
  • Single-layer Drug-in-Adhesive
  • Multi-layer Drug-in-Adhesive
  • Matrix
  • Others
• By Application:
  • Pain Relief
  • Smoking Cessation
  • Overactive Bladder
  • Hormonal Therapy
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Novartis AG
  • Purdue Pharma L.P.
  • Viatris, Inc.
  • Teikoku Pharma USA, Inc.
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • LUYE PHARMA AG
  • Samyang Holdings Corporation
  • Vektor Pharma
  • Hisamitsu Pharmaceutical Co., Inc.
  • UCB S.A.
  • Hikma Pharmaceuticals PLC 
  • Corium, Inc.
  • Nitto Denko Corporation
  • Gedeon Richter Plc.
  • Agile Therapeutics
  • Amneal Pharmaceuticals LLC.
  • Cipla
  • AdhexPharma